Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Therapeutics and DNA Methylation Inhibitors
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Azacitidine
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes